This study is in progress, not accepting new patients
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Dates
- study startedestimated completion
- Principal Investigator
- by Alain Algazi
Description
Summary
Official Title
Keywords
Eligibility
Lead Scientist at UCSF
- Alain Algazi
Associate Professor, Medicine, School of Medicine. Authored (or co-authored) 67 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Oncology Clinical Trials Information
- ID
- NCT02252042
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Last Updated